Hepatocellular carcinoma (HCC) is one of the deadliest cancers worldwide. At present, few effective biomarkers and targets are available for prognosis and treatment of HCC. Chemokines are a group of small proinflammatory chemoattractant cytokines binding to specific G-protein-coupled seven-span transmembrane receptors, which could recruit various immune cells to diverse tissues.
View Article and Find Full Text PDFROS1 rearrangement is a validated therapeutic driver gene in non-small cell lung cancer (NSCLC) and represents a small subset (1-2%) of NSCLC. A total of 17 different fusion partner genes of ROS1 in NSCLC have been reported. The multi-targeted MET/ALK/ROS1 tyrosine kinase inhibitor (TKI) crizotinib has demonstrated remarkable efficacy in ROS1-rearranged NSCLC.
View Article and Find Full Text PDFOrthodenticlehomeobox 1 (OTX1) overexpression had previously been associated with the progression of several tumors. The present study aimed to determine the expression and role of OTX1 in human hepatocellular carcinoma (HCC). The expression level of OTX1 was examined by quantitative real-time PCR (qRT-PCR) in 10 samples of HCC and paired adjacent non-cancerous tissues, and by immunohistochemistry (IHC) analysis in 128 HCC samples and matched controls.
View Article and Find Full Text PDF